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Abstract
 
Background.
 
Reverse-transcriptase inhibi-
tors have only moderate clinical efﬁcacy against the hu-
man immunodeﬁciency virus type 1 (HIV-1). Ritonavir is
an inhibitor of HIV-1 protease with potent in vitro anti-HIV
properties and good oral bioavailability.
 
Methods.
 
We evaluated the antiviral activity and safe-
ty of ritonavir in a double-blind, randomized, placebo-
controlled phase 1 and 2 study of 84 HIV-positive pa-
tients with 50 or more CD4
 

 
 lymphocytes per cubic
millimeter. The patients were randomly assigned to one
of four regimens of ritonavir therapy, or to placebo for four
weeks and then (by random assignment) to one of the
ritonavir regimens.
 
Results.
 
During the ﬁrst 4 weeks, increases in CD4
 

 
lymphocyte counts and reductions in the log number of
copies of HIV-1 RNA per milliliter of plasma were similar
among the four dosage groups, but in the three lower-
dosage groups there was a return to base-line levels by
16 weeks. After 32 weeks, in the seven patients in the
highest-dosage group (600 mg of ritonavir every 12 hours),
the median increase from base line in the CD4
 

 
 lympho-
cyte count was 230 cells per cubic millimeter, and the
mean decrease in the plasma concentration of HIV-1 RNA
(as measured by a branched-chain DNA assay) was 0.81
log (95 percent conﬁdence interval, 0.40 to 1.22). In a
subgroup of 17 patients in the two higher-dosage groups,
RNA was also measured with an assay based on the
polymerase chain reaction, and after eight weeks of treat-
ment there was a mean maximal decrease in viral RNA
of 1.94 log (95 percent conﬁdence interval, 1.37 to 2.51).
Adverse events included nausea, circumoral paresthe-
sia, elevated hepatic aminotransferase levels, and elevat-
ed triglyceride levels. Ten withdrawals from the study were
judged to be related to ritonavir treatment.
 
Conclusions.
 
In this short-term study, ritonavir was
well tolerated and had potent activity against HIV-1, but
its clinical beneﬁts remain to be established. (N Engl J
Med 1995;333:1528-33.)
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T
 
HE clinical use of nucleoside-analogue inhibitors
of reverse transcriptase is limited by toxic effects
and the emergence of mutants of the human immuno-
deﬁciency virus (HIV) that resist these drugs.
 
1
 
 HIV
type 1 (HIV-1) protease cleaves the viral Gag-Pol poly-
protein precursor into the Gag proteins and the en-
zymes integrase and protease. If the Gag-Pol precursor
molecule is not processed in this way, noninfectious
particles are formed.
 
2
 
 Inhibition of HIV-1 protease
therefore represents an attractive alternative strategy to
the inhibition of reverse transcriptase in the treatment
of HIV-1 infection.
 
3
 
The identiﬁcation of protease inhibitors with antiret-
roviral activity in vivo has been hampered by the poor
oral bioavailability of many molecules in this class. The
large size of many of these agents makes their absorp-
tion difﬁcult, and they may be rapidly cleared from plas-
ma, as has been noted with two of the ﬁrst protease in-
hibitors studied in humans, A-77003 and saquinavir.
 
4,5
 
Ritonavir is a novel inhibitor of HIV-1 protease that has
good oral bioavailability in dogs and monkeys (90 and
70 percent, respectively; unpublished data). It has po-
tent antiretroviral activity and reached high plasma con-
centrations safely in phase 1 clinical trials.
 
6
 
 Its pro-
longed absorption phase and half-life of three to four
hours permitted the use of a twice-daily dosing schedule
to achieve adequate drug levels.
 
M
 
ETHODS
 
The study was designed as a multicenter (10-site), double-blind,
placebo-controlled study. A four-week, placebo-controlled phase was
followed by a maintenance phase in which the patients continued ri-
tonavir therapy. For patients receiving antiretroviral therapy at study
entry, there was a two-week washout period before randomization.
Patients assigned to group 1 were randomly assigned to receive twice-
daily doses of 300 mg of ritonavir, 400 mg of ritonavir, or matching
placebo. After the enrollment in group 1 had been completed and half
of those patients had been treated for at least two weeks without se-
rious toxic effects, patients were assigned to group 2 and were ran-
domly assigned to receive twice-daily doses of 500 mg of ritonavir,
600 mg of ritonavir, or matching placebo. Thereafter, all the patients
were allowed to continue into the maintenance phase. During that
phase, patients who had initially been given placebo were again ran-
domly assigned, in a double-blind manner, to one of the two ritonavir
dosages used in their treatment group.
The principal criteria for inclusion in the study were as follows: age
of 18 years or older, documented HIV-1 infection, a CD4
 

 
 lympho-
cyte count greater than 50 cells per cubic millimeter as measured
twice during a three-week screening period (before the washout peri-
od), and a plasma concentration of HIV p24 antigen of 10 pg per mil-
liliter or higher. Patients were required never to have been treated
with any HIV-1 protease inhibitor, and they had to have Karnofsky
performance scores of 70 or higher. Women could participate in the
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study if they were not of child-bearing poten-
tial. All the patients gave written informed
consent.
Indicators of treatment efﬁcacy included
the CD4
 

 
 lymphocyte count and the plasma
concentrations of HIV-1 p24 antigen and vi-
ral RNA. CD4
 

 
 lymphocytes were measured
by two-color ﬂow cytometry, p24 antigen with
a commercially available kit (Abbott), and
RNA with a branched-chain DNA assay (Chi-
ron) that had a lower limit of detection of
10,000 RNA equivalents per milliliter.
 
7
 
 In a
subgroup of 17 patients, levels of viral RNA
were also measured by a more sensitive pro-
totypic quantitative polymerase-chain-reac-
tion (PCR) assay (Roche Molecular Systems).
 
8
 
Ritonavir levels were assessed by reverse high-
performance liquid chromatography, as de-
scribed elsewhere.
 
6
 
 To monitor trough con-
centrations of ritonavir, blood samples were
drawn after three and seven days of treatment
and after two, three, and four weeks. At the
end of the third week, serial blood samples
were collected over an eight-hour period to determine drug levels.
The protocol was approved by the institutional review board at each
participating center.
 
Statistical Analysis
 
The statistical analyses were performed with SAS software (ver-
sion 6.07). Demographic characteristics were compared by either
Fisher’s exact test or one-way analysis of variance. Base-line immu-
nologic and virologic measures were compared between dosage sub-
groups by the Kruskal–Wallis test and a one-way analysis of vari-
ance, respectively. Mean and median changes from base line in
measures of efﬁcacy were compared by the t-test and the Wilcoxon
rank-sum test, respectively. Mean changes from base line in selected
measures pertaining to drug safety were compared by a one-way
analysis of variance.
Pharmacokinetic measures were obtained by standard noncompart-
ment methods. These measures included the maximal concentration
of ritonavir; the time required to attain the maximal concentration in
an eight-hour period; the area under the curve for the plasma concen-
tration of ritonavir plotted against time (as computed with linear trap-
ezoidal rules); the degree of ﬂuctuation in the area under the curve
(calculated by subtracting the trough concentration from the maximal
concentration and dividing the difference by the average concentra-
tion, deﬁned as the area under the curve for an eight-hour period di-
vided by 8); the trough concentration of ritonavir; the rate of appar-
ent clearance of ritonavir (calculated by dividing the ritonavir dose by
the area under the curve estimated for a 12-hour period with the con-
centration during hour 12 by log-linear extrapolation); and the half-
life of ritonavir, which was calculated as the natural log of 2 divided
by the rate of disappearance of ritonavir from plasma between hour
6 and hour 8. 
 
R
 
ESULTS
 
Four-Week, Placebo-Controlled Phase
 
Eighty-four patients entered the study, 39 in group
1 and 45 in group 2. Their demographic characteris-
tics, risk factors for HIV infection, body weight, and
Karnofsky performance scores were similar across all
six treatment subgroups. All but three participants
were male.
Measures of efﬁcacy obtained at base line and a
summary of the previous use of antiretroviral agents in
each subgroup are shown in Table 1. When base-line
measures of efﬁcacy were compared, there were no sta-
tistically signiﬁcant differences among subgroups ex-
cept in the CD4
 

 
 lymphocyte counts in group 2: these
counts were lowest in the placebo subgroup and high-
est in the subgroup receiving 500 mg of ritonavir every
12 hours (P
 

 
0.033). The proportion of patients who
used antiretroviral therapy during the three months
before the administration of the study drug was simi-
lar in all treatment subgroups, ranging from 60 to 85
percent.
 
Measures of Efﬁcacy
 
The mean change in log concentrations of HIV-1
RNA, the median change in CD4
 

 
 lymphocyte counts,
and the median change in concentrations of HIV p24
antigen as compared with the base-line values are
shown in Figure 1. There were signiﬁcant decreases in
viral RNA and p24 antigen at one week that were sus-
tained through week 4 in all four ritonavir subgroups
(P
 

 
0.01 for the comparison with the placebo sub-
groups for both measures at all measurements). After
two weeks of treatment, increased CD4
 

 
 lymphocyte
counts were observed in the subgroups receiving 400,
500, and 600 mg of ritonavir every 12 hours; these in-
creased counts continued through week 4 and were sig-
niﬁcantly higher at all measurements than those in the
placebo subgroups (P
 

 
0.05). Increased counts were
also found among the patients with low CD4
 

 
 counts
at base line: among 29 patients with base-line CD4
 

 
lymphocyte counts below 100 cells per cubic millimeter,
22 had maximal increases of more than 100 cells per
cubic millimeter, and 8 of these had increases of at least
200 cells per cubic millimeter.
 
Pharmacokinetic Measures
 
Table 2 summarizes the pharmacokinetic measures
obtained after three weeks. Plasma concentrations of
ritonavir were higher with larger doses, with the mean
apparent clearance of the drug at day 21 remaining
relatively constant among dosage subgroups. The plas-
ma concentrations remained higher than 2.1 
 
m
 
g of
ritonavir per milliliter, the concentration estimated in
vitro to be 90 percent effective after adjustment for
binding to human plasma proteins, at almost all meas-
 
*Includes all antiretroviral medications taken in the three months before the ﬁrst administration of the study drug.
†P
 

 
0.033 for the comparison with the median CD4
 

 
 count in the placebo subgroup of group 2.
 
Table 1. Base-Line Characteristics of the Patients in the Six Study Subgroups,
According to the Treatment They Received Every 12 Hours.
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Previous use of antiret-
roviral agents 
(% of patients)*
69 69 85 73 60 67
CD4
 

 
 lymphocytes 
(cells/mm
 
3
 
)
Median
Range 
HIV p24 antigen (pg/ml)
Median
Range
Mean (
 

 
SD) HIV-1 RNA 
(log copies/ml)
98
33–395
67
25–823
5.30
 

 
0.64
143
31–456
53
13–4640
5.08
 

 
0.58
100
34–359
44
15–4797
5.33
 

 
0.51
86
11–392
75
11–631
5.25
 

 
0.63
170†
36–545
33
20–338
5.14
 

 
0.47
130
40–461
56
11–295
4.97
 

 
0.54
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urements made in patients receiving 400 mg or more
of ritonavir every 12 hours. The ratio of the maximal
concentration to the trough concentration ranged from
approximately 4.6 in the subgroup receiving 300 mg
every 12 hours to approximately 3.8 in the three sub-
groups receiving higher dosages, with ﬂuctuations over
an 8-hour period that averaged less than 1.3 for all four
subgroups.
 
Maintenance Phase
 
Seventy-six of the 84 patients who participated in the
initial four-week, placebo-controlled phase continued
ritonavir treatment or began such treatment in the
maintenance phase. The data reported here are sum-
marized according to the patients’ cumulative exposure
to ritonavir. Demographic characteristics, base-line Kar-
nofsky scores, and base-line measures of efﬁcacy were
similar among all ritonavir subgroups during the main-
tenance phase. Results are presented for up to 32 weeks
of treatment with ritonavir.
 
Measures of Efﬁcacy
 
The median change from base line in the CD4
 

 
 lym-
phocyte count and the mean change in the log concen-
tration of HIV-1 RNA are shown in Figure 2. There
were mean decreases of 0.78, 0.83, 0.97, and 1.13 log per
milliliter of plasma in the concentration of viral RNA at
week 4 in the subgroups receiving 300, 400, 500, and
600 mg of ritonavir every 12 hours, respectively. After
16 weeks of treatment with ritonavir, the mean concen-
trations of viral RNA in the 300-mg and 400-mg sub-
groups approached the base-line values once again;
there were no signiﬁcant differences between the values
obtained in these subgroups at any point during the 32
weeks of treatment. Treatment with 500 or 600 mg of
ritonavir every 12 hours produced more lasting effects
on concentrations of viral RNA. After 20 weeks of
ritonavir treatment, the mean reduction in HIV-1 RNA
in the subgroup receiving 500 mg every 12 hours be-
came smaller, whereas the size of the reduction was
sustained in the subgroup receiving 600 mg every 12
hours. There was a statistically signiﬁcant difference in
concentrations of viral RNA between these two sub-
groups at 32 weeks (P
 

 
0.010). In the 600-mg sub-
group, the mean decrease in the plasma concentration
of viral RNA was 0.81 log (95 percent conﬁdence inter-
val, 0.40 to 1.22).
Similarly, there were initial increases from base line
in median CD4
 

 
 lymphocyte counts in all the ritonavir
subgroups. In the 300-mg and the 400-mg subgroups,
the median count had returned almost to the base-line
value after 24 weeks of treatment. The 600-mg sub-
group had the largest and most sustained increase in
the median CD4
 

 
 lymphocyte count at 32 weeks of
treatment — an increase from base line of 230 cells per
cubic millimeter, measured in seven patients. This in-
crease differed signiﬁcantly from the increase in the
500-mg subgroup (P
 

 
0.030).
At two participating centers, viral RNA concentra-
tions were also assessed with a more sensitive, quan-
titative PCR assay among 17 consecutive patients in
the two subgroups receiving the highest dosages. Fig-
ure 3 shows the mean (
 

 
SD) values obtained by this
method. The mean maximal decrease, reached at
week 8, was 1.94 log (95 percent conﬁdence interval,
1.37 to 2.51). Clearly, the maximal decrease in the vi-
 
Figure 1. Immunologic and Virologic Measures during the Four-
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The top panel shows the median changes from base line in the
absolute CD4
 

 
 cell count, the middle panel the median percent-
ages of change from base line in the plasma concentration of
HIV-1 p24 antigen, and the bottom panel the mean changes in
the log number of copies of HIV-1 RNA, as measured by the
branched-DNA technique.
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ral RNA concentration was underestimated by the
branched-chain DNA assay.
 
Adverse Events and Safety
 
Most patients reported at least one adverse event: 85
to 100 percent of those treated with ritonavir during the
four-week, placebo-controlled phase and 88, 94, 95, and
100 percent of those in the 300-mg, 400-mg, 500-mg,
and 600-mg subgroups, respectively, during the main-
tenance phase. The events considered to be related to
treatment with the study drug were nausea, circumoral
paresthesia, and elevated levels of hepatic enzymes.
Among the 84 patients who entered the study, 8 with-
drew prematurely from the study during the four-week,
placebo-controlled phase, 4 of them for reasons that
were considered to be related to treatment with ri-
tonavir: 1 because of nausea, and 3 because of elevated
concentrations of aspartate aminotransferase and ala-
nine aminotransferase. Among the 76 patients who con-
tinued the study into the maintenance phase, 25 discon-
tinued treatment before the completion of all 32 weeks.
Six of these discontinuations were considered related to
treatment: three due to nausea, and three due to elevat-
ed aminotransferase concentrations.
Concentrations of aspartate aminotransferase, ala-
nine aminotransferase, cholesterol, and triglycerides in-
creased signiﬁcantly during week 1 in the subgroups re-
ceiving the two highest dosages of ritonavir, whereas in
the placebo groups there were no such increases. The
elevations in cholesterol and triglyceride concentrations
persisted throughout the 32 weeks of the study: among
all subgroups, there were increases from base line of 30
to 40 percent for cholesterol and of 200 to 300 percent
for triglycerides. During the maintenance phase, there
were only sporadic increases in aspartate aminotrans-
ferase and alanine aminotransferase. Mean concentra-
tions of alkaline phosphatase and bilirubin did not
change, nor did hemoglobin concentrations, white-cell
counts, or platelet counts.
 
D
 
ISCUSSION
 
Ritonavir has prompt and potent antiviral activity, ac-
companied by increases in the CD4
 

 
 lymphocyte count.
When we used a sensitive, PCR-based assay, the mean
maximal reduction in the plasma concentration of viral
RNA, observed after eight weeks of
treatment in 17 consecutive patients
in the subgroup receiving the highest
dosage of ritonavir, was 1.94 log.
This reduction is stronger than those
reported for reverse transcriptase in-
hibitors and other protease inhibi-
tors.
 
5,9-12
 
 Moreover, a clear relation
was found between increasing dosag-
es and the duration of the response.
The dosage of 600 mg of ritonavir
every 12 hours was best in both the
magnitude and the duration of re-
sponse. After 32 weeks of treatment,
the average decrease from base line
in viral RNA concentrations attained
with this regimen was 0.81 log, with a corresponding
median increase from base line in the CD4
 

 
 lympho-
cyte count of 230 cells per cubic millimeter (Fig. 2).
There was a partial decrease in antiviral activity
after 12 to 16 weeks of therapy with high dosages of
ritonavir. Attenuation of the antiviral effect has been
observed after 4 to 10 weeks with zidovudine
 
13
 
 or
3-thiacytidine14 and after 12 weeks with both these
agents in combination.15,16 In the case of another pro-
tease inhibitor, MK-639, loss of antiviral effect was as-
sociated with the development of resistant viral iso-
lates.17 Strains of HIV-1 that are resistant to ritonavir
have been detected during serial passages of virus in
the presence of the drug.18 Some viral isolates obtained
from patients in this study show genotypic changes,
with the wild-type valine of codon 82 frequently mutat-
ing to alanine and phenylalanine. Mutations at codons
54 (Ile→Val), 71 (Ala→Val), and 84 (Ile→Val) have
also been found. Sequential phenotypic analysis of HIV
from patients with waning responses to their viral loads
revealed the emergence of viral strains that had dimin-
ishing in vitro susceptibility to ritonavir.19,20 If the devel-
opment of resistance is the main reason for the loss of
antiviral efﬁcacy, higher doses of ritonavir resulting in
higher plasma concentrations of the drug were effective
in postponing the onset of such resistance.
This study extends the understanding of the relation
between viral load and the CD4 lymphocyte count. Re-
cently, high turnover of both viral RNA and CD4 lym-
phocytes during asymptomatic HIV-1 infection has been
reported.21,22 In our study, CD4 lymphocyte counts and
plasma concentrations of viral RNA remained at approx-
imately the base-line values in the patients receiving pla-
cebo. In the patients receiving ritonavir, steep decreases
in concentrations of viral RNA were clearly associated
with steep increases in CD4 lymphocyte counts. This
ﬁnding provides further evidence that the loss of CD4
lymphocytes in patients with HIV-1 infection is mediated
through the direct effects of the virus on infected cells or
through other processes stimulated by the presence of
HIV-1. It is unlikely that ritonavir caused CD4 lym-
phocyte counts in the peripheral blood to increase be-
cause of shifts from reservoirs in lymphoid tissue. Pa-
tients with persistent suppression of virus had lasting
increases in CD4 lymphocyte counts, whereas those
*All pharmacokinetic measures were calculated as speciﬁed in the Methods section.
†Refers to the curve formed by plotting the ritonavir concentration against time.
‡In the area under the curve.
Table 2. Mean (SD) Pharmacokinetic Measures Obtained after Three Weeks of
Treatment with Ritonavir.
MEASURE* RITONAVIR DOSE EVERY 12 HR
300 mg
(N  12)
400 mg
(N  13)
500 mg
(N  13)
600 mg
(N  10)
Time to maximal concentration (hr) 2.21.1 2.81.1 3.31.8 3.32.2
Maximal concentration (mg/ml) 5.72.5 7.12.7 10.92.6 11.23.6
Area under the curve (mg/hr/ml)† 29.714.6 39.716.4 58.518.5 60.823.4
Degree of ﬂuctuation‡ 1.260.24 1.090.36 1.190.38 1.140.36
Trough concentration (mg/ml) 1.230.88 1.901.09 2.812.14 3.032.13
Half-life of ritonavir (hr) 3.1 3.2 2.7 3.2
Apparent clearance of ritonavir (liters/hr) 10.03.9 9.53.7 7.72.4 8.93.2
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on July 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 1995 Massachusetts Medical Society. All rights reserved. 
1532 THE NEW ENGLAND JOURNAL OF MEDICINE Dec. 7, 1995
who did not maintain reduced concentrations of viral
RNA had concomitant losses of CD4 lymphocytes de-
spite constant exposure to ritonavir.
Adverse events, mainly nausea and circumoral pares-
thesia, occurred frequently but were tolerated by most
patients, leading to the withdrawal of ritonavir in only
four patients. Increases in aspartate aminotransferase
and alanine aminotransferase concentrations that were
considered to be drug-related were seen mainly during
the ﬁrst weeks of treatment and led to the withdrawal of
another six patients. The dose-dependent increase in
triglyceride concentrations, whose mechanism is unclear,
was asymptomatic and not associated with evidence of
pancreatitis. The maximal tolerated dosage of ritonavir
was not determined, although the appearance of nausea
and of elevations in hepatic aminotransferase concentra-
tions suggests that the dosage of 600 mg every 12 hours
approaches the maximum.
Pharmacokinetic considerations had a prominent
role in this study. A low in vitro concentration of riton-
avir (approximately 0.10 mM) was found to be 90 per-
cent effective against HIV-1 type IIIB in MT4 cells in
a conventional growth medium containing 10 percent
fetal-calf serum.6 Ritonavir is 99 percent bound to
plasma proteins; therefore, the 90 percent effective
concentration found in the absence of high serum pro-
tein levels may underestimate the drug concentrations
required to exert a similar effect in vivo. Experiments
with ritonavir showed a progressive increase in the 90
percent effective concentration when in vitro testing
medium contained progressively higher levels of hu-
man serum. Protease inhibitors diffuse freely across
the cell membrane, and therefore the concentration of
free drug in plasma may reﬂect concentrations of the
drug inside cells23 (and Norbeck DW: personal com-
munication). The functional 90 percent effective con-
centration, after adjustment for binding to protein, ap-
peared to be about 3 mM (approximately 2.1 mg per
milliliter). The dosages in our study were selected to
yield drug concentrations above this value. The target-
ed effective concentration was reached, and all four
dosage subgroups had initially substantial reductions
in the viral load. However, longer-lasting effects on
CD4 lymphocytes and viral RNA were observed only
in the dosage subgroups in which the mean trough
concentrations of ritonavir exceeded the 90 percent ef-
fective concentration.
These early results with ritonavir monotherapy show
potent antiviral and immunostimulatory effects. The
precise clinical beneﬁt conferred by ritonavir remains
to be established. The possibility of extending the re-
ductions in viral RNA achieved with ritonavir mono-
Figure 2. Changes from Base Line during the Maintenance
Phase of Treatment, Lasting up to a Total of 32 Weeks, Accord-
ing to Dosage Subgroup.
Changes in median CD4 lymphocyte counts (upper panel)
and in mean concentrations of HIV-1 RNA as measured by the
branched-DNA assay (lower panel) are shown. Some patients
missed a measurement but returned for subsequent
measurements.
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Figure 3. Changes from Base Line in the Mean (SD) Concen-
tration of HIV-1 RNA as Measured by a More Sensitive PCR As-
say in 17 Consecutive Patients in the Subgroups Receiving 500
mg and 600 mg of Ritonavir Every 12 Hours during the Mainte-
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Some patients missed a measurement but returned for subse-
quent measurements.
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therapy requires further study in which this agent is
used in combination with reverse-transcriptase inhibi-
tors and other protease inhibitors.
We are indebted to Judy Smith, R.N., for constant support in co-
ordinating the study; to John Sninsky (Roche Molecular Systems,
Alameda, Calif.) for providing the prototype of the PCR assay for
HIV RNA; to Joep M.A. Lange, M.D. (National AIDS Therapy Eval-
uation Center, the Netherlands), for constructive comments; to Rich
Hippensteel, M.S., and Scott Madarik, M.S., for statistical support; to
Jill R. Burke and Philip Cunningham, B.Sc., for technical support;
and to the patients who participated in the study.
APPENDIX
In addition to the study authors, the European–Australian Collab-
orative Ritonavir Study Group included the following persons: Hospi-
tal Clinico de Valencia — C. Gimeno; Hospital Germans Trias i Pujol
— B. Clotet and J. Tor; Hospital de Bellvitge “Principes de España”
— E. Ferrer; Hospital La Paz — P.L. Martinez; Hospital General Gre-
gorio Marañon — S. Moreno and G. Zancada; Hospital 12 de Octu-
bre — J. Alcami, A.R. Noriega, and F. Pulido; and Abbott Laborato-
ries — H.N. Glassman.
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